Bruno Paiva, PhD, from the University of Navarra, Pamplona, Spain, urges hematologists and oncologists interested in monitoring MRD in patients with multiple myeloma to only use validated, optimised next-generation techniques that have been recommended by the International Myeloma Working Group. Either NGS by Adaptive, the commercial vendor, or next-generation flow. Bruno discusses the availability of these techniques and the factors to consider when deciding which to use.

свернуть